Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Simply Wall StNov 15 20:08

Seres Therapeutics Price Target Maintained With a $10.00/Share by Canaccord Genuity

Dow JonesNov 15 00:20 · Ratings

Seres Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow JonesNov 15 00:20 · Ratings

Promising Developments and Financial Stability Drive Buy Rating for Seres Therapeutics

TipRanksNov 14 20:26 · Ratings

Seres Therapeutics Reports Q3 2024 Results and Strategic Progress

TipRanksNov 14 12:03

Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

BenzingaNov 14 07:56 · Ratings